Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1

Conditions

Stomach Neoplasms 1Osteosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced or Metastatic Solid Tumors 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

Ifosfamide 6Leucovorin 5Doxorubicin 4Dexrazoxane 4Cisplatin 4Methotrexate 3Filgrastim 3Carboplatin 3mifamurtide 2glucarpidase 2Radiotherapy 2Neoadjuvant Therapy 2Mesna 2Granulocyte-Macrophage Colony-Stimulating Factor 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Cryosurgery 2Chemotherapy, Adjuvant 2temsirolimus 1sintilimab 1sargramostim 1saracatinib 1samarium Sm-153 lexidronam 1robatumumab 1pembrolizumab 1pegfilgrastim 1pazopanib 1omburtamab I-131 1niraparib 1lexatumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Osteosarcoma × sintilimab × Clear all
NCT04861948 2022-10-04

IBI188 Combination Therapy in Solid Tumors

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Terminated
9 enrolled
SarcomaThoracic

Adenocarcinoma of Lung, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡